Cancer diagnostics company Pacific Edge has failed in its attempted legal challenge of a US decision halting public funding for its Cxbladder tests through the Medicare system.
With hours remaining before the funding cut comes into force, a District Court in Pennsylvania ruled it did not have
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
